316 related articles for article (PubMed ID: 25894803)
41. Anti-obesity drugs: a review about their effects and their safety.
Derosa G; Maffioli P
Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
[TBL] [Abstract][Full Text] [Related]
42. Contemporary medical, device, and surgical therapies for obesity in adults.
Perdomo CM; Cohen RV; Sumithran P; Clément K; Frühbeck G
Lancet; 2023 Apr; 401(10382):1116-1130. PubMed ID: 36774932
[TBL] [Abstract][Full Text] [Related]
43. Well-being of obese individuals: therapeutic perspectives.
Chaput JP; Tremblay A
Future Med Chem; 2010 Dec; 2(12):1729-33. PubMed ID: 21428796
[TBL] [Abstract][Full Text] [Related]
44. Weight management in people with type 2 diabetes.
Wu L; While A
Br J Community Nurs; 2007 Sep; 12(9):390-7. PubMed ID: 18026001
[TBL] [Abstract][Full Text] [Related]
45. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Apovian CM
Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
[TBL] [Abstract][Full Text] [Related]
46. [Nutrition-obesity. Rimonabant and cardiovascular risk factors].
Vincent M; Golay A
Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325
[TBL] [Abstract][Full Text] [Related]
47. Metabolic risk factors, drugs, and obesity.
Padwal R; Majumdar S
N Engl J Med; 2006 Mar; 354(9):974-5; author reply. PubMed ID: 16510755
[No Abstract] [Full Text] [Related]
48. Why do we need drugs to treat the patient with obesity?
Bray GA
Obesity (Silver Spring); 2013 May; 21(5):893-9. PubMed ID: 23520198
[TBL] [Abstract][Full Text] [Related]
49. Reducing the risk of obesity: defining the role of weight loss drugs.
Ling H; Lenz TL; Burns TL; Hilleman DE
Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
[TBL] [Abstract][Full Text] [Related]
50. FDA-Approved Anti-Obesity Drugs in the United States.
Daneschvar HL; Aronson MD; Smetana GW
Am J Med; 2016 Aug; 129(8):879.e1-6. PubMed ID: 26949003
[TBL] [Abstract][Full Text] [Related]
51. Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
Wilding JPH
Clin Obes; 2018 Jun; 8(3):211-225. PubMed ID: 29689646
[TBL] [Abstract][Full Text] [Related]
52. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
Verspohl EJ
Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127
[No Abstract] [Full Text] [Related]
53. New advances in models and strategies for developing anti-obesity drugs.
Kim GW; Lin JE; Blomain ES; Waldman SA
Expert Opin Drug Discov; 2013 Jun; 8(6):655-71. PubMed ID: 23621300
[TBL] [Abstract][Full Text] [Related]
54. The use of lorcaserin in the management of obesity: a critical appraisal.
Bai B; Wang Y
Drug Des Devel Ther; 2010 Dec; 5():1-7. PubMed ID: 21267355
[TBL] [Abstract][Full Text] [Related]
55. Interface between pharmacotherapy and genes in human obesity.
O'Connor A; Swick AG
Hum Hered; 2013; 75(2-4):116-26. PubMed ID: 24081227
[TBL] [Abstract][Full Text] [Related]
56. JAMA PATIENT PAGE. Specific Medications for Weight Loss.
Jin J
JAMA; 2015 Aug; 314(7):742. PubMed ID: 26284734
[No Abstract] [Full Text] [Related]
57. Medications as adjunct therapy for weight loss: approved and off-label agents in use.
Moyers SB
J Am Diet Assoc; 2005 Jun; 105(6):948-59. PubMed ID: 15942547
[TBL] [Abstract][Full Text] [Related]
58. Pharmacotherapy for the management of obesity.
Patel D
Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
[TBL] [Abstract][Full Text] [Related]
59. Treatment modalities of obesity: what fits whom?
Hainer V; Toplak H; Mitrakou A
Diabetes Care; 2008 Feb; 31 Suppl 2():S269-77. PubMed ID: 18227496
[TBL] [Abstract][Full Text] [Related]
60. The new role of pharmacotherapy for weight reduction in obesity.
Fernstrom MH; Fernstrom JD
Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
